PACB vs DHR

For growth investors, Pacific Biosciences of California, Inc.

(PACB) is the stronger pick with 3. 9% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Danaher Corporation (DHR) offers the better valuation at 34. 9x trailing P/E (20. 8x forward), making it the more compelling value choice. Analysts rate Pacific Biosciences of California, Inc. (PACB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Danaher Corporation (DHR) delivered a total return of -21.

1%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: DHR returned +219. 3% versus PACB's -81. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.

94β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 159% more volatile than DHR relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pacific Biosciences of California, Inc.

(PACB) is pulling ahead at 3. 9% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Danaher Corporation grew EPS -4. 7% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, PACB leads at 7. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Danaher Corporation (DHR) is the more profitable company, earning 14.

7% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps 14. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DHR leads at 20. 9% versus -348. 5% for PACB. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DHR: 40.

6% to $247. 00.

In this comparison, DHR (0.

7% yield) pays a dividend. PACB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

94), 0. 7% yield, +219. 3% 10Y return). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHR: +219. 3%, PACB: -81. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

DHR pays a dividend while PACB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.